The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Dalbavancin-Global Market Insights and Sales Trends 2024
Synopsis
Dalbavancin is a novel second-generation lipoglycopeptide antibiotic. It belongs to the same class as vancomycin, the most widely used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA).
The global Dalbavancin market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Dalbavancin in various end use industries. The expanding demands from the Skin Infection, Soft Tissue Infection and Others,, are propelling Dalbavancin market. Intravenous Therapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Oral Type segment is estimated at % CAGR for the next seven-year period.
Dabavan star is a new antibiotic developed by Durata, named Dalvance, which was approved by FDA to be marketed in the United States on May 23, 2014. It is used to treat complex acute bacterial skin and skin structure infections in adults. The drug is a second-generation glycopeptide antibiotic given intravenously.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Dalbavancin, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Dalbavancin market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Dalbavancin market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Dalbavancin sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Dalbavancin covered in this report include Roche, Pfizer, Abbvie, Johnson, Sanofi, Merck, Novartis, Gilead and GSK, etc.
The global Dalbavancin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche
Pfizer
Abbvie
Johnson
Sanofi
Merck
Novartis
Gilead
GSK
Amgen
Hayao
Global Dalbavancin market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Dalbavancin market, Segment by Type:
Intravenous Therapy
Oral Type
Global Dalbavancin market, by Application
Skin Infection
Soft Tissue Infection
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Dalbavancin manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Dalbavancin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Dalbavancin is a novel second-generation lipoglycopeptide antibiotic. It belongs to the same class as vancomycin, the most widely used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA).
The global Dalbavancin market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Dalbavancin in various end use industries. The expanding demands from the Skin Infection, Soft Tissue Infection and Others,, are propelling Dalbavancin market. Intravenous Therapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Oral Type segment is estimated at % CAGR for the next seven-year period.
Dabavan star is a new antibiotic developed by Durata, named Dalvance, which was approved by FDA to be marketed in the United States on May 23, 2014. It is used to treat complex acute bacterial skin and skin structure infections in adults. The drug is a second-generation glycopeptide antibiotic given intravenously.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Dalbavancin, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Dalbavancin market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Dalbavancin market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Dalbavancin sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Dalbavancin covered in this report include Roche, Pfizer, Abbvie, Johnson, Sanofi, Merck, Novartis, Gilead and GSK, etc.
The global Dalbavancin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche
Pfizer
Abbvie
Johnson
Sanofi
Merck
Novartis
Gilead
GSK
Amgen
Hayao
Global Dalbavancin market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Dalbavancin market, Segment by Type:
Intravenous Therapy
Oral Type
Global Dalbavancin market, by Application
Skin Infection
Soft Tissue Infection
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Dalbavancin manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Dalbavancin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Dalbavancin Market Overview
1.1 Dalbavancin Product Overview
1.2 Dalbavancin Market Segment by Type
1.2.1 Intravenous Therapy
1.2.2 Oral Type
1.3 Global Dalbavancin Market Size by Type
1.3.1 Global Dalbavancin Market Size Overview by Type (2018-2029)
1.3.2 Global Dalbavancin Historic Market Size Review by Type (2018-2023)
1.3.3 Global Dalbavancin Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Dalbavancin Sales Breakdown by Type (2018-2023)
1.4.2 Europe Dalbavancin Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Dalbavancin Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Dalbavancin Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Dalbavancin Sales Breakdown by Type (2018-2023)
2 Global Dalbavancin Market Competition by Company
2.1 Global Top Players by Dalbavancin Sales (2018-2023)
2.2 Global Top Players by Dalbavancin Revenue (2018-2023)
2.3 Global Top Players by Dalbavancin Price (2018-2023)
2.4 Global Top Manufacturers Dalbavancin Manufacturing Base Distribution, Sales Area, Product Type
2.5 Dalbavancin Market Competitive Situation and Trends
2.5.1 Dalbavancin Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Dalbavancin Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Dalbavancin as of 2022)
2.7 Date of Key Manufacturers Enter into Dalbavancin Market
2.8 Key Manufacturers Dalbavancin Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Dalbavancin Status and Outlook by Region
3.1 Global Dalbavancin Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Dalbavancin Historic Market Size by Region
3.2.1 Global Dalbavancin Sales in Volume by Region (2018-2023)
3.2.2 Global Dalbavancin Sales in Value by Region (2018-2023)
3.2.3 Global Dalbavancin Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Dalbavancin Forecasted Market Size by Region
3.3.1 Global Dalbavancin Sales in Volume by Region (2024-2029)
3.3.2 Global Dalbavancin Sales in Value by Region (2024-2029)
3.3.3 Global Dalbavancin Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Dalbavancin by Application
4.1 Dalbavancin Market Segment by Application
4.1.1 Skin Infection
4.1.2 Soft Tissue Infection
4.1.3 Others
4.2 Global Dalbavancin Market Size by Application
4.2.1 Global Dalbavancin Market Size Overview by Application (2018-2029)
4.2.2 Global Dalbavancin Historic Market Size Review by Application (2018-2023)
4.2.3 Global Dalbavancin Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Dalbavancin Sales Breakdown by Application (2018-2023)
4.3.2 Europe Dalbavancin Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Dalbavancin Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Dalbavancin Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Dalbavancin Sales Breakdown by Application (2018-2023)
5 North America Dalbavancin by Country
5.1 North America Dalbavancin Historic Market Size by Country
5.1.1 North America Dalbavancin Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Dalbavancin Sales in Volume by Country (2018-2023)
5.1.3 North America Dalbavancin Sales in Value by Country (2018-2023)
5.2 North America Dalbavancin Forecasted Market Size by Country
5.2.1 North America Dalbavancin Sales in Volume by Country (2024-2029)
5.2.2 North America Dalbavancin Sales in Value by Country (2024-2029)
6 Europe Dalbavancin by Country
6.1 Europe Dalbavancin Historic Market Size by Country
6.1.1 Europe Dalbavancin Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Dalbavancin Sales in Volume by Country (2018-2023)
6.1.3 Europe Dalbavancin Sales in Value by Country (2018-2023)
6.2 Europe Dalbavancin Forecasted Market Size by Country
6.2.1 Europe Dalbavancin Sales in Volume by Country (2024-2029)
6.2.2 Europe Dalbavancin Sales in Value by Country (2024-2029)
7 Asia-Pacific Dalbavancin by Region
7.1 Asia-Pacific Dalbavancin Historic Market Size by Region
7.1.1 Asia-Pacific Dalbavancin Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Dalbavancin Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Dalbavancin Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Dalbavancin Forecasted Market Size by Region
7.2.1 Asia-Pacific Dalbavancin Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Dalbavancin Sales in Value by Region (2024-2029)
8 Latin America Dalbavancin by Country
8.1 Latin America Dalbavancin Historic Market Size by Country
8.1.1 Latin America Dalbavancin Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Dalbavancin Sales in Volume by Country (2018-2023)
8.1.3 Latin America Dalbavancin Sales in Value by Country (2018-2023)
8.2 Latin America Dalbavancin Forecasted Market Size by Country
8.2.1 Latin America Dalbavancin Sales in Volume by Country (2024-2029)
8.2.2 Latin America Dalbavancin Sales in Value by Country (2024-2029)
9 Middle East and Africa Dalbavancin by Country
9.1 Middle East and Africa Dalbavancin Historic Market Size by Country
9.1.1 Middle East and Africa Dalbavancin Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Dalbavancin Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Dalbavancin Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Dalbavancin Forecasted Market Size by Country
9.2.1 Middle East and Africa Dalbavancin Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Dalbavancin Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Roche
10.1.1 Roche Company Information
10.1.2 Roche Introduction and Business Overview
10.1.3 Roche Dalbavancin Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Roche Dalbavancin Products Offered
10.1.5 Roche Recent Development
10.2 Pfizer
10.2.1 Pfizer Company Information
10.2.2 Pfizer Introduction and Business Overview
10.2.3 Pfizer Dalbavancin Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Pfizer Dalbavancin Products Offered
10.2.5 Pfizer Recent Development
10.3 Abbvie
10.3.1 Abbvie Company Information
10.3.2 Abbvie Introduction and Business Overview
10.3.3 Abbvie Dalbavancin Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Abbvie Dalbavancin Products Offered
10.3.5 Abbvie Recent Development
10.4 Johnson
10.4.1 Johnson Company Information
10.4.2 Johnson Introduction and Business Overview
10.4.3 Johnson Dalbavancin Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Johnson Dalbavancin Products Offered
10.4.5 Johnson Recent Development
10.5 Sanofi
10.5.1 Sanofi Company Information
10.5.2 Sanofi Introduction and Business Overview
10.5.3 Sanofi Dalbavancin Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Sanofi Dalbavancin Products Offered
10.5.5 Sanofi Recent Development
10.6 Merck
10.6.1 Merck Company Information
10.6.2 Merck Introduction and Business Overview
10.6.3 Merck Dalbavancin Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Merck Dalbavancin Products Offered
10.6.5 Merck Recent Development
10.7 Novartis
10.7.1 Novartis Company Information
10.7.2 Novartis Introduction and Business Overview
10.7.3 Novartis Dalbavancin Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Novartis Dalbavancin Products Offered
10.7.5 Novartis Recent Development
10.8 Gilead
10.8.1 Gilead Company Information
10.8.2 Gilead Introduction and Business Overview
10.8.3 Gilead Dalbavancin Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Gilead Dalbavancin Products Offered
10.8.5 Gilead Recent Development
10.9 GSK
10.9.1 GSK Company Information
10.9.2 GSK Introduction and Business Overview
10.9.3 GSK Dalbavancin Sales, Revenue and Gross Margin (2018-2023)
10.9.4 GSK Dalbavancin Products Offered
10.9.5 GSK Recent Development
10.10 Amgen
10.10.1 Amgen Company Information
10.10.2 Amgen Introduction and Business Overview
10.10.3 Amgen Dalbavancin Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Amgen Dalbavancin Products Offered
10.10.5 Amgen Recent Development
10.11 Hayao
10.11.1 Hayao Company Information
10.11.2 Hayao Introduction and Business Overview
10.11.3 Hayao Dalbavancin Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Hayao Dalbavancin Products Offered
10.11.5 Hayao Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Dalbavancin Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Dalbavancin Industrial Chain Analysis
11.4 Dalbavancin Market Dynamics
11.4.1 Dalbavancin Industry Trends
11.4.2 Dalbavancin Market Drivers
11.4.3 Dalbavancin Market Challenges
11.4.4 Dalbavancin Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Dalbavancin Distributors
12.3 Dalbavancin Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
